Seaport Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 21.1 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.13B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company’s lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.
Details
| Name | Seaport Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 58 |
| Founded | 2024 |
| Ipo Date | 2026-05-01 |
| Ceo | Daphne Zohar |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 18.00 |
| Isin | US81221K1088 |
| Cusip | 81221K108 |
| Cik | 2042347 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Daphne Zohar | Founder, Chief Executive Officer, President and Director |
| Dr. Steven M. Paul M.D. | Founder and Non-Employee Chair of the Board |
| Dr. Michael Cunyuan Chen Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Antony Loebel M.D. | Chief Medical Officer and President of Clinical Development |
| Lauren A. White M.B.A. | Chief Financial Officer |
| Lana Gladstein J.D. | General Counsel |
Contact
| Address | 101 Seaport Blvd., Floor 12, Boston, Massachusetts 02210-2186, United States |
| Phone | (617) 807-4062 |
| Website | https://www.seaporttx.com |